Company profile: Biomaneo
1.1 - Company Overview
Company description
- Provider of medical analysis kits for the detailed analysis of proteins by mass spectrometry.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Biomaneo
La Jolla Pharmaceutical
HQ: United States
Website
- Description: Provider of biopharmaceutical therapeutics focused on discovery, development and commercialization for chronic organ failure and cancer. Products include GIAPREZA (angiotensin II) to increase blood pressure in adults with septic or other distributive shock, XERAVA (eravacycline) for complicated intra-abdominal infections, and XACDURO for hospital-acquired and ventilator-associated bacterial pneumonia; pipeline includes GCS-100 and investigational zoliflodacin for uncomplicated gonorrhea.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full La Jolla Pharmaceutical company profile →
Endovascular Engineering
HQ: United States
Website
- Description: Provider of preclinical mechanical thrombectomy solutions, including the Hēlo™ G1 Thrombectomy System for non-surgical removal of thrombi and emboli from venous vasculature. Features include a self-expanding funnel with wide distal opening for large bore clot engagement, dual-action high-speed agitation with physician-controlled aspiration, and a single-pass catheter with integrated handle for navigating complex anatomies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Endovascular Engineering company profile →
Disc Medicine
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies for hematologic diseases and rare blood disorders, including Bitopertin, an oral GlyT1 inhibitor for erythropoietic porphyrias and abnormal erythropoiesis; DISC-0974, an injectable monoclonal antibody targeting hemojuvelin (HJV) to suppress hepcidin for anemias of inflammation; and DISC-3405, an injectable monoclonal antibody inhibiting TMPRSS6 to increase hepcidin for polycythemia vera and iron overload.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Disc Medicine company profile →
Veralox Therapeutics
HQ: United States
Website
- Description: Provider of small molecule therapeutics targeting the 12-LOX pathway for thrombosis and Type 1 Diabetes. Products include VLX-1005, a first-in-class drug for treating Heparin-Induced Thrombocytopenia by inhibiting platelet activation through 12-LOX pathway inhibition; VLX-2000 Series under development to protect β cells and improve insulin production; plus an Expanded Access Program for investigational medicines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Veralox Therapeutics company profile →
SynGen
HQ: United States
Website
- Description: Provider of advanced cell separation tools and accessories for regenerative medicine workflows, inventing and commercializing single-use sterile plastic cartridge disposables mated to dedicated, highly automated electromechanical medical devices to isolate and capture stem and progenitor cells from peripheral and umbilical cord blood and bone marrow.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SynGen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Biomaneo
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Biomaneo
2.2 - Growth funds investing in similar companies to Biomaneo
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Biomaneo
4.2 - Public trading comparable groups for Biomaneo
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →